OCULAR THERAPEUTIX, INC Restructuring and Related Cost, Number of Positions Eliminated
OCULAR THERAPEUTIX, INC (OCUL) had Restructuring and Related Cost, Number of Positions Eliminated of 37 employee as of 2024-05-29, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Restructuring and Related Cost, Positions Eliminated
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2024-11-14
- 2024-05-29: Restructuring and Related Cost, Number of Positions Eliminated 37.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2024-05-29 | 37.00 employee 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |